Eli Lilly and Company (NYSE:LLY) Shares Acquired by Goldstone Financial Group LLC

Goldstone Financial Group LLC boosted its stake in shares of Eli Lilly and Company (NYSE:LLY) by 43.3% in the fourth quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The firm owned 420 shares of the company’s stock after purchasing an additional 127 shares during the quarter. Goldstone Financial Group LLC’s holdings in Eli Lilly and Company were worth $324,000 at the end of the most recent reporting period.

Other institutional investors have also recently added to or reduced their stakes in the company. Channel Wealth LLC boosted its holdings in shares of Eli Lilly and Company by 11.4% during the fourth quarter. Channel Wealth LLC now owns 8,504 shares of the company’s stock valued at $6,565,000 after acquiring an additional 870 shares during the period. Capital Planning LLC lifted its position in Eli Lilly and Company by 15.6% in the 4th quarter. Capital Planning LLC now owns 481 shares of the company’s stock valued at $371,000 after purchasing an additional 65 shares during the last quarter. KMG Fiduciary Partners LLC boosted its stake in Eli Lilly and Company by 3.3% during the 4th quarter. KMG Fiduciary Partners LLC now owns 26,361 shares of the company’s stock valued at $20,350,000 after purchasing an additional 831 shares during the period. Decker Retirement Planning Inc. bought a new position in Eli Lilly and Company in the 4th quarter worth about $189,000. Finally, Occidental Asset Management LLC increased its stake in shares of Eli Lilly and Company by 1.2% in the fourth quarter. Occidental Asset Management LLC now owns 1,475 shares of the company’s stock valued at $1,139,000 after purchasing an additional 18 shares during the period. 82.53% of the stock is currently owned by institutional investors.

Wall Street Analysts Forecast Growth

A number of equities analysts recently issued reports on the company. Redburn Atlantic raised Eli Lilly and Company to a “hold” rating in a report on Monday, November 4th. Truist Financial increased their price target on Eli Lilly and Company from $1,000.00 to $1,033.00 and gave the stock a “buy” rating in a research note on Thursday, October 10th. Bank of America restated a “buy” rating and set a $997.00 price objective on shares of Eli Lilly and Company in a research note on Tuesday, December 10th. Citigroup increased their target price on shares of Eli Lilly and Company from $1,060.00 to $1,250.00 and gave the company a “buy” rating in a research report on Friday, October 25th. Finally, StockNews.com raised shares of Eli Lilly and Company from a “hold” rating to a “buy” rating in a research note on Wednesday, January 1st. Four investment analysts have rated the stock with a hold rating and eighteen have issued a buy rating to the stock. According to MarketBeat, the company currently has an average rating of “Moderate Buy” and a consensus price target of $1,002.22.

Insider Activity at Eli Lilly and Company

In other Eli Lilly and Company news, CAO Donald A. Zakrowski sold 900 shares of Eli Lilly and Company stock in a transaction that occurred on Friday, November 8th. The shares were sold at an average price of $803.38, for a total transaction of $723,042.00. Following the transaction, the chief accounting officer now directly owns 5,480 shares in the company, valued at approximately $4,402,522.40. The trade was a 14.11 % decrease in their position. The transaction was disclosed in a document filed with the SEC, which is accessible through this hyperlink. 0.13% of the stock is owned by insiders.

Eli Lilly and Company Stock Performance

Shares of NYSE LLY opened at $726.24 on Friday. The stock’s fifty day simple moving average is $783.25 and its 200 day simple moving average is $856.02. The stock has a market capitalization of $689.43 billion, a price-to-earnings ratio of 78.51, a PEG ratio of 1.66 and a beta of 0.41. The company has a quick ratio of 0.97, a current ratio of 1.27 and a debt-to-equity ratio of 2.03. Eli Lilly and Company has a 52-week low of $612.70 and a 52-week high of $972.53.

Eli Lilly and Company (NYSE:LLY) last issued its quarterly earnings results on Wednesday, October 30th. The company reported $1.18 earnings per share for the quarter, missing analysts’ consensus estimates of $1.52 by ($0.34). The company had revenue of $11.44 billion during the quarter, compared to analysts’ expectations of $12.09 billion. Eli Lilly and Company had a return on equity of 71.08% and a net margin of 20.48%. The company’s revenue for the quarter was up 20.4% compared to the same quarter last year. During the same period in the prior year, the business posted $0.10 EPS. As a group, sell-side analysts forecast that Eli Lilly and Company will post 13.14 earnings per share for the current fiscal year.

Eli Lilly and Company Increases Dividend

The company also recently declared a quarterly dividend, which will be paid on Monday, March 10th. Stockholders of record on Friday, February 14th will be issued a dividend of $1.50 per share. The ex-dividend date is Friday, February 14th. This represents a $6.00 dividend on an annualized basis and a dividend yield of 0.83%. This is a positive change from Eli Lilly and Company’s previous quarterly dividend of $1.30. Eli Lilly and Company’s payout ratio is currently 56.22%.

Eli Lilly and Company declared that its Board of Directors has authorized a share repurchase plan on Monday, December 9th that allows the company to buyback $15.00 billion in outstanding shares. This buyback authorization allows the company to buy up to 2% of its stock through open market purchases. Stock buyback plans are usually a sign that the company’s management believes its stock is undervalued.

About Eli Lilly and Company

Eli Lilly and Company discovers, develops, and markets human pharmaceuticals worldwide. The company offers Basaglar, Humalog, Humalog Mix 75/25, Humalog U-100, Humalog U-200, Humalog Mix 50/50, insulin lispro, insulin lispro protamine, insulin lispro mix 75/25, Humulin, Humulin 70/30, Humulin N, Humulin R, and Humulin U-500 for diabetes; Jardiance, Mounjaro, and Trulicity for type 2 diabetes; and Zepbound for obesity.